Chondrosarcoma local recurrence in the Cancer Registry of Norway cohort (1990-2013): Patterns and impact.

Autor: Thorkildsen J; Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Cancer Registry of Norway, Oslo, Norway., Norum OJ; Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway., Myklebust TA; Cancer Registry of Norway, Oslo, Norway.; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway., Zaikova O; Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
Jazyk: angličtina
Zdroj: Journal of surgical oncology [J Surg Oncol] 2021 Feb; Vol. 123 (2), pp. 510-520. Date of Electronic Publication: 2020 Dec 14.
DOI: 10.1002/jso.26308
Abstrakt: Background: There appears to be an association between local recurrence (LR) and risk of metastasis and death in central conventional chondrosarcoma (CCCS) of bone, but this has not been quantified in modern cohorts at a subtype level.
Methods: We identified nonmetastatic cases of CCCS (N = 180) from the Cancer Registry of Norway. We present prognostic analysis of LR accounting for immortal time bias by descriptive statistics and multivariable Cox models.
Results: Of 40 LR, one case demonstrated upgrading while two dedifferentiation. LR was associated with increased risk of metastasis (hazard ratio [HR] = 4.1 [confidence interval, 1.5-10.7]) and death (HR = 9.3 [5.0-17.5]) overall. LR was associated with significant increased risk of metastasis for those with a soft tissue component, axial location, malignancy grade 2, but not atypical cartilaginous tumor's, appropriately treated curettage patients, intramedullary tumors, grade 1 histology, extremity location or "Oslo low risk" group status. We found an increased risk of death for all groups except for those treated by appropriate curettage or belonging to the "Oslo low risk" group. About 50% of LR CCCS were asymptomatic and revealed by routine follow-up.
Conclusions: Upgrading of LR for CCCS was a seldom event. LR was associated with significant increased risk of metastasis and death overall, but not for appropriately treated curettage patients or "Oslo low risk" status.
(© 2020 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: